AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05923502 — intervention group
Intervention type: DRUG
Intervention: Duvelisib
Description: This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Study NCT06483685 — intervention group
Intervention type: DRUG
Intervention: Radiopharmaceuticals drugs
Description: radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
Study NCT04921878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
Study NCT06468267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
Study NCT04366518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Transdermal System
Description: Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
Study NCT04366518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
Study NCT04366518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
Study NCT04366518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
Study NCT04735198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor surgery
Description: Large bowel resection.
Study NCT04735198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary tumor surgery
Description: Large bowel resection.
Study NCT04735198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
Description: Large bowel resection combined and cholecystectomy.
Study NCT04716218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: back up head elevated position
Description: The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
Study NCT04716218 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: back up head elevated position
Description: The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
Study NCT05246384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP7214
Description: RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
Study NCT06386445 — intervention group
Intervention type: OTHER
Intervention: Serum metabolomics sequencing
Description: Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
Study NCT05700578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Elimination for Traumatic Stress (SBETS)
Description: This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
Study NCT05700578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modifiable Behavior Intervention (MoBI)
Description: The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Study NCT06438692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VOM ethanol chemical ablation and 2C3L
Description: Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
Study NCT06438692 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 2C3L
Description: Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized chat-based interactions
Description: Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text message
Description: Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study NCT04772521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study NCT04772521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mailed nicotine replacement therapy (NRT)
Description: Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
Study NCT04772521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT)
Description: Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
Study NCT04928469 — intervention group
Intervention type: OTHER
Intervention: No intervention performed
Description: Collection of clinical and laboratory data
Study NCT06449508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
Study NCT06124586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Description: Percutaneous transluminal angioplasty of the leg
Study NCT06124586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty
Description: Percutaneous transluminal angioplasty of the leg
Study NCT06184906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weaning by Mediterranean Diet
Description: Introduce solid foods typical of the Mediterranean Diet at weaning of infants
Study NCT06184906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weaning by Mediterranean Diet
Description: Introduce solid foods typical of the Mediterranean Diet at weaning of infants
Study NCT05061485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: The participants consume A) water with 75 g sucrose
Study NCT05061485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose + protein
Description: The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
Study NCT05061485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose + fat
Description: The participants C) water with 75 g sucrose + approx. 100 kcal fat
Study NCT05974956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastitis care teaching protocol
Description: It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
Study NCT04781647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: Participants will receive ETV 0.5 mg tablets orally once daily
Study NCT04781647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFNα
Description: Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
Study NCT04781647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFNα
Description: Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
Study NCT06071520 — intervention group
Intervention type: DRUG
Intervention: Fostamatinib
Description: Patient treated with fostamatinib in the period described
Study NCT05392387 — intervention group
Intervention type: OTHER
Intervention: Standard antiviral therapy
Description: pegylated interferon or/and nucleos(t)ide analogues
Study NCT05888181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-management intervention
Description: The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B).
Study NCT05476666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripherial and central venous access
Description: Passing a peripherial and a central venous catheter/cannula
Study NCT04904783 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radiotherapy
Description: Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
Study NCT04758676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and physiotherapy protocol, BIA
Description: Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
Study NCT04758676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Study subjects will receive the current standard of care.
Study NCT06009172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA)
Description: Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
Study NCT05660330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic semi-tailormade well-being intervention
Description: The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
Study NCT04757714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
Description: The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
Study NCT04757714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
Description: a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
Study NCT04757714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: * a physical activity questionnaire (PHAS instrument)~* a COPD quality of life questionnaire (St George Hospital)
Study NCT04757714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A search for sarcopenia by studying the strength of the grip (dynamometer)
Description: A search for sarcopenia by studying the strength of the grip (dynamometer)
Study NCT05905133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: subcutaneous injection
Study NCT05721300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments
Description: NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）
Study NCT05721300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments
Description: patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks
Study NCT04958759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
Study NCT04958759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
Study NCT04958759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: The program will be consist of 10 weeks of breathing exercises
Study NCT06112795 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT04709341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Band 60MIN
Description: TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
Study NCT04709341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR Band 120MIN
Description: TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
Study NCT05133258 — intervention group
Intervention type: OTHER
Intervention: Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension
Description: Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
Study NCT06199271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and dalpiciclib
Description: Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
Study NCT05605561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Story
Description: It is the standard of care given according to the hospital's policies and procedures.
Study NCT06284434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
Study NCT06284434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
Study NCT06284434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
Study NCT06284434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
Study NCT05247476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-T4
Description: Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Study NCT05247476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-T4+T3 (thyroid tablet)
Description: Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.